Non-steroidal anti-inflammatory drugs and bladder cancer prevention

Inclusion of phenacetin among ‘proven’ human carcinogens by the IARC in 1987, raised concerns about the carcinogenic potential of acetaminophen, its major metabolite. Acetaminophen has been implicated as a possible causal agent in the development of cancer of the renal pelvis. The bladder and renal pelvis, which derive from the same embryological structure, share the same transitional type of epithelium. Past studies have been inconclusive on the possible relationship among these analgesics and bladder cancer but no large, highly detailed study of this association has been conducted. A population-based case–control study conducted in Los Angeles, California, involved 1514 incident bladder cancer cases and an equal number of controls who were matched to the index cases by sex, date of birth (within 5 years) and race. Detailed information on medication use and prior medical conditions was collected through in-person interviews. Regular use of analgesics was not associated with an increased risk of bladder cancer in either men or women. In fact, compared with non- or irregular users, regular analgesic users were at a decreased risk of bladder cancer overall (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68–0.96). However, there were clear differences in both the direction and strength of the associations between the different formulation classes of analgesics and bladder cancer risk. Intake of phenacetin was positively related to bladder cancer risk in a dose-dependent manner while intake of its major metabolite in humans, acetaminophen, was unrelated to risk. Intake of all classes of NSAIDs, except pyrazolon derivatives, were negatively associated with bladder cancer risk, with suggestive evidence that the protective effect varies in strength by subcategories of formulation. Acetic acids seemed to exhibit the strongest protective effect, whereas aspirin/other salicylic acids and oxicam showed the weakest protection. © 2000 Cancer Research Campaign

[1]  B. Flaks,et al.  Induction by paracetamol of bladder and liver tumours in the rat. Effects on hepatocyte fine structure. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[2]  S. Johansson,et al.  Tumours of urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[3]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[4]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.

[5]  M. Yu,et al.  Regular use of analgesics is a risk factor for renal cell carcinoma , 1999, British Journal of Cancer.

[6]  K. Wakabayashi,et al.  Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. , 1998, Cancer research.

[7]  E. Okajima,et al.  Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. , 1997, Carcinogenesis.

[8]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. , 1997, Cancer research.

[9]  D. Rose,et al.  Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. , 1996, Cancer research.

[10]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[11]  H. Jick,et al.  Acetaminophen and Renal and Bladder Cancer , 1996, Epidemiology.

[12]  V. Steele,et al.  Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. , 1996, Carcinogenesis.

[13]  R. DuBois,et al.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.

[14]  A. Lupulescu.  Prostaglandins, their inhibitors and cancer. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[15]  M. Schuler.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[16]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[17]  R. DuBois,et al.  The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. , 1995, European journal of cancer.

[18]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[19]  J. Haseman,et al.  Long‐term Exposure to the Anti‐inflammatory Agent Phenylbutazone Induces Kidney Tumors in Rats and Liver Tumors in Mice , 1995, Japanese journal of cancer research : Gann.

[20]  F. Marks,et al.  Differential expression of prostaglandin h synthase isozymes during multistage carcinogenesis in mouse epidermis , 1995, Molecular carcinogenesis.

[21]  L. Wilkins.  Is the incidence of dementing illness changing? A 25‐year time trend study in Rochester, Minnesota (1960–1984) , 1994, Neurology.

[22]  J. Falgueyret,et al.  Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. , 1994, Molecular pharmacology.

[23]  S. Fukushima,et al.  Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model , 1993, International journal of cancer.

[24]  S. Makino,et al.  Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain. , 1993, Cancer research.

[25]  V. Steele,et al.  Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. , 1993, Carcinogenesis.

[26]  M. Thun,et al.  Aspirin use and risk of fatal cancer. , 1993, Cancer research.

[27]  L. Marnett.  Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.

[28]  S. Cohen,et al.  Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. , 1989, Cancer research.

[29]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[30]  G. Matanoski,et al.  Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. , 1985, The New England journal of medicine.

[31]  T. Fujii,et al.  Carcinogenicity testing of acetaminophen in F344 rats. , 1985, Japanese journal of cancer research : Gann.

[32]  M. McCredie,et al.  Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. , 1983, British journal of urology.

[33]  M. McCredie,et al.  Analgesics and cancer of the renal pelvis in New South Wales , 1982, Cancer.

[34]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[35]  S. Johansson,et al.  Carcinogenicity of analgesics: Long‐term treatment of sprague‐dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen) , 1981, International journal of cancer.

[36]  W. Fokkens.  Phenacetin abuse related to bladder cancer. , 1979, Environmental research.

[37]  L. Angervall,et al.  Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. , 1969, British journal of urology.

[38]  A. Ljungqvist,et al.  Carcinoma of the renal pelvis in renal papillary necrosis. , 1965, Acta chirurgica Scandinavica.

[39]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[40]  V. Steele,et al.  Chemopreventive drug development: perspectives and progress. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  V. Steele,et al.  Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. , 1993, Anticancer research.

[42]  G. Kelloff,et al.  Chemoprevention of experimental bladder cancer. , 1992, Journal of cellular biochemistry. Supplement.

[43]  G. Kelloff,et al.  Chemoprevention of exprimental bladder cancer , 1992 .

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[45]  M. McCredie,et al.  Does paracetamol cause urothelial cancer or renal papillary necrosis? , 1988, Nephron.

[46]  S. Cohen,et al.  Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. , 1984, Carcinogenesis.

[47]  N. Breslow,et al.  The analysis of case-control studies , 1980 .